Business
CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practices In a
About this update from Waldencast Plc
[{"type":"text","content":"Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practices\nIn a release issued under the same headline earlier today by Waldencast plc (NASDAQ: WALD), please note that the quote by Michael Pennington in paragraph 3 was incorrect. The corrected release follows: NEW YORK and DALLAS, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Platinum Dermatology Partners as the launch partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. Platinum will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs. “This collaboration with Obagi very much matches our objectives and ethos to expand our capabilities in clinical research to advance the highest level of aesthetic medicine,” said Michael Pennington, Chief Executive Officer and Co-founder of Platinum Dermatology Partners. “Our injectors treat patients every day. That experience matters. This is the kind of work we should be doing. Obagi is thinking differently about product development, and that aligns with how we approach patient care.” The ALOHA Real-World Program is designed to give Platinum providers hands-on experience with Obagi saypha MagIQ while evaluating complete Obagi protocols. This approach aims to drive patient satisfaction and strengthen relationships between patients and their Platinum providers. The program includes a real-world clinical initiative supplemented by a structured evaluation process across multiple Platinum practices and providers, with standardized data capture. Platinum will present initial findings at this September's annual Platinum Summit in Dallas, highlighting the benefits of the new product and its protocols within the Platinum network. Results will also be presented at key industry conferences to demonstrate the real-world impact of introducing this innovative injectable across Platinum’s practices. “Partnering with Platinum is a clear statement of our intent to launch this new injectable on a foundation of robust clinical evidence, educatio...